EP1191941A4 - A method for the prophylaxis and/or treatment of medical disorders - Google Patents

A method for the prophylaxis and/or treatment of medical disorders

Info

Publication number
EP1191941A4
EP1191941A4 EP00936560A EP00936560A EP1191941A4 EP 1191941 A4 EP1191941 A4 EP 1191941A4 EP 00936560 A EP00936560 A EP 00936560A EP 00936560 A EP00936560 A EP 00936560A EP 1191941 A4 EP1191941 A4 EP 1191941A4
Authority
EP
European Patent Office
Prior art keywords
prophylaxis
treatment
medical disorders
disorders
medical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00936560A
Other languages
German (de)
French (fr)
Other versions
EP1191941A1 (en
Inventor
Christopher John Wraight
George Arthur Werther
Stephanie Ruth Edmondson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Murdoch Childrens Research Institute
Original Assignee
Murdoch Childrens Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Murdoch Childrens Research Institute filed Critical Murdoch Childrens Research Institute
Publication of EP1191941A1 publication Critical patent/EP1191941A1/en
Publication of EP1191941A4 publication Critical patent/EP1191941A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/335—Modified T or U
EP00936560A 1999-06-21 2000-06-21 A method for the prophylaxis and/or treatment of medical disorders Withdrawn EP1191941A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14034599P 1999-06-21 1999-06-21
US140345P 1999-06-21
PCT/AU2000/000693 WO2000078341A1 (en) 1999-06-21 2000-06-21 A method for the prophylaxis and/or treatment of medical disorders

Publications (2)

Publication Number Publication Date
EP1191941A1 EP1191941A1 (en) 2002-04-03
EP1191941A4 true EP1191941A4 (en) 2006-12-13

Family

ID=22490818

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00936560A Withdrawn EP1191941A4 (en) 1999-06-21 2000-06-21 A method for the prophylaxis and/or treatment of medical disorders

Country Status (6)

Country Link
EP (1) EP1191941A4 (en)
JP (1) JP2003502383A (en)
AU (1) AU768904B2 (en)
CA (1) CA2376284A1 (en)
NZ (1) NZ515964A (en)
WO (1) WO2000078341A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020165196A1 (en) * 2001-05-07 2002-11-07 Eric Wickstrom Oligonucleotide inhibitors of cancer cell proliferation
AU2002365374A1 (en) * 2001-11-28 2003-06-10 Angiogenetics Sweden Ab Regulation of hypoxia-inducible gene expression with antisense inhibitory pas domain protein
US20030158143A1 (en) * 2002-01-17 2003-08-21 Martin Gleave Bispecific antisense olignucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same
AU2003207708A1 (en) * 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
SI2264172T1 (en) 2002-04-05 2017-12-29 Roche Innovation Center Copenhagen A/S Oligomeric compounds for the modulation of hif-1alpha expression
JP2007529993A (en) * 2003-07-02 2007-11-01 シンジェンタ パーティシペーションズ アーゲー Glucanases, nucleic acids encoding them and methods for making and using them
CA2533218C (en) 2003-08-05 2014-11-18 Avi Biopharma, Inc. Oligonucleotide analog and method for treating flavivirus infections
WO2005030260A1 (en) 2003-10-01 2005-04-07 The University Of British Columbia Bispecific oligonucleotide for the treatment of cns malignancies
US8618054B2 (en) 2004-05-05 2013-12-31 Valorisation-Rechereche Société en Commandite Interleukin-1 receptor antagonists, compositions, and methods of treatment
HUE028632T2 (en) 2004-06-28 2016-12-28 Univ Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
EA014097B1 (en) 2004-11-09 2010-08-30 Сантарис Фарма А/С Potent lna oligonucleotides for modulating of hif-1a expression and use thereof
US9447138B2 (en) 2004-11-09 2016-09-20 Roche Innovation Center Copenhagen A/S Potent LNA oligonucleotides for the inhibition of HIF-1a expression
CA2650656A1 (en) 2005-05-05 2007-01-11 Valorisation Hsj, Societe En Commandite Cytokine receptor modulators and uses thereof
JP2009522312A (en) * 2005-12-29 2009-06-11 アルコン リサーチ， リミテッド RNAi-mediated inhibition of IGF1R for the treatment of ocular angiogenesis
EP2405270B1 (en) * 2006-06-30 2013-07-17 Merck Sharp & Dohme Corp. IGFBP2-Biomarker
WO2008113773A2 (en) * 2007-03-16 2008-09-25 Biorigen S.R.L. Gene expression regulation technology and noncoding rnas for diagnosis and therapy
DK3133160T3 (en) 2008-10-24 2019-04-01 Sarepta Therapeutics Inc EXON SKIP COMPOSITIONS FOR DMD
CN102387817B (en) * 2009-02-12 2018-01-30 库尔纳公司 By suppressing to treat the related diseases of BDNF for the natural antisense transcript of neurotrophic factor derived from brain (BDNF)
US20120252869A1 (en) * 2009-07-24 2012-10-04 Opko Curna, Llc Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
KR101805213B1 (en) * 2009-08-21 2017-12-06 큐알엔에이, 인크. Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip
KR102239374B1 (en) 2009-11-12 2021-04-14 더 유니버시티 오브 웨스턴 오스트레일리아 Antisense Molecules and Methods for Treating Pathologies
ES2842938T3 (en) * 2012-01-11 2021-07-15 Ionis Pharmaceuticals Inc Compositions and Methods for IKBKAP Splice Modulation
CA2906209A1 (en) 2013-03-14 2014-09-25 Sarepta Therapeutics, Inc. Exon skipping compositions for treating muscular dystrophy targeting the annealing site h44a (-07+15)
US9506058B2 (en) 2013-03-15 2016-11-29 Sarepta Therapeutics, Inc. Compositions for treating muscular dystrophy
NO344051B1 (en) * 2017-05-04 2019-08-26 Patogen As Novel virus in Fish and Method for detection

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995008567A1 (en) * 1993-09-20 1995-03-30 Celtrix Pharmaceuticals, Inc. Treatment of immunologic and hematologic disorders with igfbp alone or complexed with igf
AU692278B2 (en) * 1994-07-08 1998-06-04 Murdoch Childrens Research Institute, The A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders
AUPM672594A0 (en) * 1994-07-08 1994-08-04 Royal Children's Hospital Research Foundation A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders
SE9501472D0 (en) * 1995-04-21 1995-04-21 Pharmacia Ab Truncated IGF-I

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BARRECA A ET AL: "IN-VITRO PARACRINE REGULATION OF HUMAN KERATINOCYTE GROWTH BY FIBROBLAST-DERIVED INSULIN-LIKE GROWTH FACTORS", JOURNAL OF CELLULAR PHYSIOLOGY, vol. 151, no. 2, 1992, pages 262 - 268, XP002402612, ISSN: 0021-9541 *
GREAVES MALCOLM W ET AL: "Treatment of psoriasis", NEW ENGLAND JOURNAL OF MEDICINE, vol. 332, no. 9, 1995, pages 581 - 588, XP009073585, ISSN: 0028-4793 *
See also references of WO0078341A1 *
WRAIGHT C J ET AL: "REVERSAL OF EPIDERMAL HYPERPROLIFERATION IN PSORIASIS BY INSULIN-LIKE GROWTH FACTOR I RECEPTOR ANTISENSE OLIGONUCLEOTIDES", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 18, no. 5, May 2002 (2002-05-01), pages 521 - 526, XP001172823, ISSN: 1087-0156 *

Also Published As

Publication number Publication date
AU768904B2 (en) 2004-01-08
JP2003502383A (en) 2003-01-21
AU5202000A (en) 2001-01-09
NZ515964A (en) 2004-03-26
WO2000078341A8 (en) 2001-03-22
CA2376284A1 (en) 2000-12-28
WO2000078341A1 (en) 2000-12-28
EP1191941A1 (en) 2002-04-03

Similar Documents

Publication Publication Date Title
EP1191941A4 (en) A method for the prophylaxis and/or treatment of medical disorders
AU2001247331A1 (en) Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
HUP0104966A3 (en) A medical system and a method of controlling the system for use by a patient for medical self treatment
EP1509279A4 (en) Device and method for the treatment of cardiac disorders
HUP0400914A3 (en) Methods of treatment of mitochondrial disorders
EP1455778A4 (en) Methods for the treatment of peripheral neural and vascular ailments
IL151890A0 (en) Hydroxyphenyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
HK1044944A1 (en) 1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives for the treatment of cns disorders
AU6910600A (en) Methods for the treatment of mental disorders
EP1239855A4 (en) Method for the prevention and/or treatment of atherosclerosis
EP1126850A4 (en) Treatment of disorders of the outer retina
HUP0200738A3 (en) Method of the treatment of incontinence
AU6330999A (en) Rhodanine derivatives for the treatment and prevention of metabolic bone disorders
IL151891A0 (en) Quinolinyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
IL151765A0 (en) Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain
GB9922752D0 (en) Medical devices and treatment and prophylaxis
EP1181308A4 (en) Methods for the treatment of neuronal atrophy-associated dementia
AU6331099A (en) Thiazolidine derivatives for the treatment and prevention of metabolic bone disorders
CZ20011872A3 (en) Isonipecotamides for the treatment of integrin-mediated disorders
IL162053A0 (en) Method for the treatment of bone disorders
AU2566201A (en) Compounds and methods for the treatment of pain
AU2420101A (en) Method and composition for the treatment of pain
IL150202A0 (en) Method and composition for the treatment of pain
SG99857A1 (en) A method of treatment and prophylaxis
IL150208A0 (en) Compound and method for the treatment of pain

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020116

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20020116;LT PAYMENT 20020116;LV PAYMENT 20020116;MK PAYMENT 20020116;RO PAYMENT 20020116;SI PAYMENT 20020116

A4 Supplementary search report drawn up and despatched

Effective date: 20061109

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070103